No­vo Nordisk slammed with an RTF as the FDA rais­es CMC is­sues

No­vo Nordisk’s block­buster di­a­betes drug Ozem­pic (semaglu­tide) has al­ready made the Dan­ish drug­mak­er bil­lions of dol­lars, and the com­pa­ny is aim­ing to cap­i­tal­ize on that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.